IHS Chemical Week

Chemical Week Magazine :: Pharmaceuticals & Fine Chemicals

FDA Charges Ranbaxy with Falsifying Data at India Plant

11:11 AM MST | March 6, 2009 | DEEPTI RAMESH

The U.S. FDA has charged Ranbaxy Laboratories (Gurgaon, India) with falsifying data and test results in approved and pending drug applications at the company’s Paonta Sahib, India facility. The agency says it has stopped reviewing new or pending drug approval applications from the plant, which has been under an FDA import alert since last September for deviating from U.S. cGMP (CW, Sept. 22, 2008, p. 4). Ranbaxy says it will co-operate with FDA. Woodcock: ‘Companies must provide truthful and accurate information.’ Applications that are affected...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2014 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa